Ascletis Pharma announced new data presentations at the 33rd European Congress on Obesity, highlighting their obesity drug candidates. ASC47 combined with semaglutide showed up to 111.8% greater weight loss compared to semaglutide alone. ASC36 demonstrated a much longer half-life and superior weight loss effects in preclinical models compared to existing treatments. These advancements suggest potential new effective therapies for obesity management, with further clinical development anticipated.
Taco Bell Canada introduced two new menu items: Crispy Chicken Nuggets with a Jalapeño Honey Mustard sauce, and Mountain Dew Baja Midnight, the first new Mountain Dew Baja Blast flavor in over 20 years. The nuggets feature all-white meat with Mexican...
VERAXA Biotech updated on its progress in developing novel cancer therapies using its proprietary BiTAC platform, focusing on conditionally active T cell engagers and bispecific antibody-drug conjugates. The company plans to prioritize investment in ...
Nexans and Hydro have agreed on a five-year contract for about 85,000 tonnes of low-carbon aluminium wire rod to support Europe's electricity grid modernization. This aluminium, produced using 100% renewable energy in Norway, will help reduce carbon ...
Nexans and Hydro have agreed on a five-year supply contract for about 85,000 tons of low-carbon aluminum wire rod to support the modernization and decarbonization of Europe's electrical grid. The aluminum, produced in Norway using 100% renewable ener...
Scilex Holding Company announced a binding term sheet with Kazakhstan-based iHolding Group LLP for a $100 million investment, purchasing about 6.67 million shares at $15 each. This funding aims to support Scilex's strategic growth in healthcare, prod...
